Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Niclosamide

            Therapeutic Area: Infections and Infectious Diseases Product Name: UNI91103

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 22, 2021

            Details:

            UNION therapeutics A/S (UNION) has been selected by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge to trial UNI91103 as a prophylactic treatment of COVID-19 in kidney patients, a vulnerable and high-risk patient population.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GBS-NN

            Therapeutic Area: Infections and Infectious Diseases Product Name: GBS-NN

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: $57.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing December 15, 2020

            Details:

            Proceeds will advance the clinical development of MinervaX’s novel GBS vaccine through Phase II clinical trials, as well as manufacturing and regulatory preparation for Phase III.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Niclosamide

            Therapeutic Area: Infections and Infectious Diseases Product Name: UNI91103

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 21, 2020

            Details:

            Niclosamide based nasal spray (UNI91103) will first be investigated in high risk patients to test its ability to prevent infection with COVID-19 and to reduce the severity of the disease for those already infected.